Buy Aarti Drugs; target of Rs 848: Anand Rathi

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

live

• bselive
• nselive

Volume

Todays L/H

More

×

Anand Rathi's research report on Aarti Drugs

Aarti’s Q3 FY21 margins surpassed our expectation. Its EBITDA margin expanded 569bps to 19.9%, driven by better realisations in APIs and import-duty imposition on key products such as ciprofloxacin. Sales grew 12% to Rs.5.3bn. The API division contributed 87% to sales and grew 13.1% to Rs.4.6bn. Formulations sales were up 5.2% to Rs.697m. Through organic growth and capacity addition, Aarti expects sales to record a 15% CAGR over FY21-26 to Rs.45bn and the EBITDA margin to scale up to 24-25%.

Outlook

We raise our FY21e/FY22e/FY23e EPS 8%/7.6%/5.2%. We retain our Buy rating and raise our target to Rs.848 (earlier Rs.813) based on 18x FY23e earnings.

For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Read More